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considering a similar biological pattern to radioinduced cystitis. 2 studies with these characteristics were found, showing that
HA instillations are effective in radioinduced cystitis prevention.
Conclusions. Intravesical instillations of hyaluronic acid are effective in preventing radiation cystitis. It is safe and well toler-
ated. Given the scarcity reports on this subject, it is difﬁcult to draw any ﬁrm conclusion about standard recommendations. A
prospective randomized control study with a large number of patients is recommended.
http://dx.doi.org/10.1016/j.rpor.2013.03.016
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Introduction. In 1999, American Brachytherapy Society (ABS) proposed prostate contour as clinical target volume (CTV) on prostate
brachytherapy. Many authors still use this CTV. In 2007 ESTRO recommended two new CTV according to risk of extraprostatic
extension (EPE): • CTV(ESTRO1) =prostate + 3mm around. • CTV(ESTRO2) =prostate + 3mm around excluding the rectal wall.
Purpose. 1. To demonstrate that CTV(ESTRO2) is the most appropriated to current knowledge on local development of prostate
cancer. 2. It is possible to obtain fair seed distributions respecting doses to target and organs at risk.
Methods and materials. Ninety-eight patients with low-risk prostate cancer treated with 125I seeds (dose 145Gy; CTV=prostate)
were included. Average age was 68.79 years, mean PSA was 6.30ng/ml. New CTV(ESTRO2) was deﬁned for every patients and
new planning was performed.
Results. Mean risk of EPE is 28.46% of which 15.93% are in the posterior direction. A CTV(ESTRO2) was planned for every case.
The mean CTV doses: V 100: 95.74%, V150: 47.65%, D90: 160.22Gy and organs at risk: Urethra D30: 190.70Gy and D10: 203.21Gy.
Rectum D2cc: 96.74Gy and D0.1cc: 183.50Gy All of them got a theoretical distribution of seeds that provided a curative dose to
this new CTV and respected the limiting dose for organs at risk. As expected, this extended CTV yield more dose to rectum but
not exceeding limitations. Urethral doses were similar in both plans.
Conclusion. CTV(ABS) seems to be insufﬁcient when risk of EPE is considered. CTV(ESTRO1) is excessive because the rectum,
which in most instances is inside the 3mm extension, is rarely involved by tumor. CTV(ESTRO2) seems to be suitable and it is
possible to plan the CTV proposed and obtain fair dosimetric results for CTV and organs at risk.
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Introduction. The prognosis of conservative treatment in choroidal melanoma, is marked by a number of factors with varying
degrees of signiﬁcance. It has found as an independent prognostic factor in the rapid regression of tumor after brachytherapy.
Dose rate is an important factor for the radiobiological viewpoint. The speed is early regression is indicative of metastasis.
Purpose. To correlate dose rate at the apex of tumor with speed of regression of the tumor height. To classify the treatments
performed according to the dose rate used. To study the relationship between the dose rate and disease-free survival of patients
treated with episcleral brachytherapy.
Method. Observational, retrospective and prospective study. Patients with uveal melanoma treated in our hospital by episcleral
brachytherapy with I-125. Descriptive variables of prognostic value regarding tumor data, data with respect to the applicator,
visual acuity both before treatment and in successive and scheduled revisions and survival data of patients and whether or not
disease free.
Results. Positive correlation was found between the dose rate and the rate of regression of the maximum height of the tumor.
However, the dose rate at the apex has no correlation with the change of size of the base nor changes in visual acuity. The dose
rate in the organs at risk is not related to changes in visual acuity.
Conclusions. Dose rate at apex tumor inﬂuences rate of regression of tumor height. So, you might have to be a prognostic factor.
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